<p>藥明康德（NYSE:PRGO - 獲取免費報告）在週六發佈的報告中被 StockNews.com 的分析師從 “買入” 評級下調至 “持有” 評級。</p>
<p>其他股票分析師最近也對該公司發佈了報告。Piper Sandler 將藥明康德的評級從 “增持” 下調至 “中性”，並在 1 月 6 日的研究報告中將其目標價從 34.00 美元下調至 27.00 美元。Jefferies Financial Group 在 9 月 23 日的研究報告中重申了 “持有” 評級，並將藥明康德的目標價設定為 30.00 美元（之前為 50.00 美元）。最後，Canaccord Genuity Group 在 9 月 30 日的研究報告中重申了 “買入” 評級，並將藥明康德的目標價設定為 42.00 美元。三位研究分析師對該股票給予了 “持有” 評級，兩位分析師給予了 “買入” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，共識目標價為 35.00 美元。</p>
<p><strong>獲取我們最新的 PRGO 股票報告</strong></p>
<h2>藥明康德股價下跌 2.6%</h2>
<p>PRGO 股票在週五開盤價為 24.41 美元。該股票的 50 日移動平均線為 26.77 美元，200 日移動平均線為 26.81 美元。該公司的債務與股本比率為 0.94，速動比率為 1.77，流動比率為 2.56。該公司的市值為 33.3 億美元，市盈率為-20.86，貝塔值為 0.53。藥明康德的 52 周低點為 23.89 美元，52 周高點為 33.96 美元。</p>
<p>藥明康德（NYSE:PRGO - 獲取免費報告）最近在 11 月 6 日發佈了其財報。該公司報告季度每股收益（EPS）為 0.81 美元，符合分析師的共識預期 0.81 美元。藥明康德的股本回報率為 7.38%，淨利潤率為-3.64%。該公司在本季度的收入為 10.9 億美元，而共識預期為 11.2 億美元。去年同期，該公司每股收益為 0.64 美元。該公司本季度的收入同比下降了 3.2%。研究分析師預計藥明康德在當前財政年度的每股收益將達到 2.56 美元。</p>
<h2>內部人士買賣</h2>
<p>在其他新聞中，董事 Jeffrey B. Kindler 在 12 月 9 日的交易中出售了 17,598 股公司的股票。該股票以 28.27 美元的平均價格出售，總價值為 497,495.46 美元。出售後，該董事現在直接持有 5,409 股公司股票，價值 152,912.43 美元。這代表了他們持有的股票減少了 76.49%。該出售在與證券交易委員會的法律文件中披露，該文件可通過 SEC 網站獲取。當前 0.70% 的股票由公司內部人士持有。</p>
<h2>對藥明康德的對沖基金看法</h2>
<p>幾家大型投資者最近增加或減少了對 PRGO 的持股。Wealth Enhancement Advisory Services LLC 在第四季度將其在藥明康德的持股增加了 2.1%。Wealth Enhancement Advisory Services LLC 現在持有 21,617 股公司股票，價值 567,000 美元，此前在上個季度又購買了 436 股。Voisard Asset Management Group Inc.在第三季度將其在藥明康德的持股增加了 9.7%。Voisard Asset Management Group Inc.現在持有 5,100 股公司股票，價值 134,000 美元，此前在上個季度又購買了 450 股。Central Pacific Bank Trust Division 在第四季度將其在藥明康德的持股增加了 33.3%。Central Pacific Bank Trust Division 現在持有 2,000 股公司股票，價值 51,000 美元，此前在此期間又購買了 500 股。Creative Planning 在第三季度將其在藥明康德的持股增加了 3.7%。Creative Planning 現在持有 18,477 股公司股票，價值 485,000 美元，此前在此期間又購買了 661 股。最後，亞利桑那州退休系統在第二季度將其在藥明康德的持股增加了 1.9%。亞利桑那州退休系統現在持有 37,939 股公司股票，價值 974,000 美元，此前在此期間又購買了 699 股。當前 95.91% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>藥明康德公司簡介</h2>
<p>（獲取免費報告）</p>
<p>藥明康德公司提供非處方健康和保健解決方案，以提升個人在美國、歐洲和國際上的福祉。它通過消費者自我護理美洲和消費者自我護理國際兩個部門運營。該公司開發、製造、營銷和分銷自我護理消費品，如上呼吸道產品，包括止咳藥、祛痰藥以及鼻竇和過敏緩解藥；營養產品，包括嬰兒配方奶粉和營養飲料；消化健康產品，包括抗酸藥、止瀉藥和抗胃灼熱藥；止痛和助眠產品，包括止痛藥和退燒藥；以及口腔護理產品，包括牙刷、牙刷替換頭、牙線、牙線棒、美白產品和牙刷保護套。</p>
<h2>精選文章</h2>
<ul>
<li>我們更喜歡的五隻股票比藥明康德更好</li>
<li>哪些華爾街分析師最準確？</li>
<li>向前推進：Lucid 的銷售增長和 Gravity SUV 的影響</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>為什麼亞馬遜的下一個財報可能會引發股票突破</li>
<li>10 美元以下的最佳股票</li>
<li>有了這種數據，美聯儲今年不會降息</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
<p>在你考慮藥明康德之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而培瑞克並不在名單上。</p>
<p>雖然培瑞克目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

培瑞克

<p>培瑞克（NYSE:PRGO）被 StockNews.com 從 “買入” 評級下調至 “持有” 評級。其他分析師，包括 Piper Sandler 和 Jefferies Financial Group，也調整了對該股票的評級和目標價格。目前，培瑞克的共識評級為 “持有”，目標價格為 35.00 美元。該股票開盤價為 24.41 美元，下跌 2.6%，市值為 33.3 億美元。最近的財報顯示每股收益為 0.81 美元，與預期相符，但收入同比下降了 3.2%。還注意到內部交易活動，一位董事出售了大量股份</p>

<p>Perrigo (NYSE:PRGO - Get Free Report) was downgraded by analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report issued on Saturday.</p>
<div class="lb-trans"><p>藥明康德（NYSE:PRGO - 獲取免費報告）在週六發佈的報告中被 StockNews.com 的分析師從 “買入” 評級下調至 “持有” 評級。</p>
</div><p>Other equities analysts also recently issued reports about the company. Piper Sandler downgraded Perrigo from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and dropped their target price for the company from $34.00 to $27.00 in a research report on Monday, January 6th. Jefferies Financial Group reiterated a &#34;hold&#34; rating and issued a $30.00 price objective (down previously from $50.00) on shares of Perrigo in a research note on Monday, September 23rd. Finally, Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a $42.00 price objective on shares of Perrigo in a research note on Monday, September 30th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $35.00.</p>
<div class="lb-trans"><p>其他股票分析師最近也對該公司發佈了報告。Piper Sandler 將藥明康德的評級從 “增持” 下調至 “中性”，並在 1 月 6 日的研究報告中將其目標價從 34.00 美元下調至 27.00 美元。Jefferies Financial Group 在 9 月 23 日的研究報告中重申了 “持有” 評級，並將藥明康德的目標價設定為 30.00 美元（之前為 50.00 美元）。最後，Canaccord Genuity Group 在 9 月 30 日的研究報告中重申了 “買入” 評級，並將藥明康德的目標價設定為 42.00 美元。三位研究分析師對該股票給予了 “持有” 評級，兩位分析師給予了 “買入” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，共識目標價為 35.00 美元。</p>
</div><p><strong>Get Our Latest Stock Report on PRGO</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 PRGO 股票報告</strong></p>
</div><h2>Perrigo Trading Down 2.6 %</h2>
<div class="lb-trans"><h2>藥明康德股價下跌 2.6%</h2>
</div><p>Shares of PRGO stock opened at $24.41 on Friday. The stock's fifty day moving average is $26.77 and its two-hundred day moving average is $26.81. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. The firm has a market capitalization of $3.33 billion, a P/E ratio of -20.86 and a beta of 0.53. Perrigo has a fifty-two week low of $23.89 and a fifty-two week high of $33.96.</p>
<div class="lb-trans"><p>PRGO 股票在週五開盤價為 24.41 美元。該股票的 50 日移動平均線為 26.77 美元，200 日移動平均線為 26.81 美元。該公司的債務與股本比率為 0.94，速動比率為 1.77，流動比率為 2.56。該公司的市值為 33.3 億美元，市盈率為-20.86，貝塔值為 0.53。藥明康德的 52 周低點為 23.89 美元，52 周高點為 33.96 美元。</p>
</div><p>Perrigo (NYSE:PRGO - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.81 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.81. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the company earned $0.64 EPS. The company's revenue for the quarter was down 3.2% on a year-over-year basis. Research analysts expect that Perrigo will post 2.56 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>藥明康德（NYSE:PRGO - 獲取免費報告）最近在 11 月 6 日發佈了其財報。該公司報告季度每股收益（EPS）為 0.81 美元，符合分析師的共識預期 0.81 美元。藥明康德的股本回報率為 7.38%，淨利潤率為-3.64%。該公司在本季度的收入為 10.9 億美元，而共識預期為 11.2 億美元。去年同期，該公司每股收益為 0.64 美元。該公司本季度的收入同比下降了 3.2%。研究分析師預計藥明康德在當前財政年度的每股收益將達到 2.56 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other news, Director Jeffrey B. Kindler sold 17,598 shares of the company's stock in a transaction on Monday, December 9th. The stock was sold at an average price of $28.27, for a total value of $497,495.46. Following the sale, the director now directly owns 5,409 shares in the company, valued at $152,912.43. This represents a 76.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.70% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Jeffrey B. Kindler 在 12 月 9 日的交易中出售了 17,598 股公司的股票。該股票以 28.27 美元的平均價格出售，總價值為 497,495.46 美元。出售後，該董事現在直接持有 5,409 股公司股票，價值 152,912.43 美元。這代表了他們持有的股票減少了 76.49%。該出售在與證券交易委員會的法律文件中披露，該文件可通過 SEC 網站獲取。當前 0.70% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Perrigo</h2>
<div class="lb-trans"><h2>對藥明康德的對沖基金看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in PRGO. Wealth Enhancement Advisory Services LLC grew its stake in shares of Perrigo by 2.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 21,617 shares of the company's stock valued at $567,000 after buying an additional 436 shares in the last quarter. Voisard Asset Management Group Inc. lifted its holdings in shares of Perrigo by 9.7% in the 3rd quarter. Voisard Asset Management Group Inc. now owns 5,100 shares of the company's stock worth $134,000 after purchasing an additional 450 shares during the last quarter. Central Pacific Bank Trust Division increased its position in Perrigo by 33.3% in the 4th quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company's stock valued at $51,000 after acquiring an additional 500 shares during the period. Creative Planning increased its position in shares of Perrigo by 3.7% during the 3rd quarter. Creative Planning now owns 18,477 shares of the company's stock valued at $485,000 after purchasing an additional 661 shares during the period. Finally, Arizona State Retirement System increased its position in shares of Perrigo by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 37,939 shares of the company's stock valued at $974,000 after purchasing an additional 699 shares during the period. 95.91% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家大型投資者最近增加或減少了對 PRGO 的持股。Wealth Enhancement Advisory Services LLC 在第四季度將其在藥明康德的持股增加了 2.1%。Wealth Enhancement Advisory Services LLC 現在持有 21,617 股公司股票，價值 567,000 美元，此前在上個季度又購買了 436 股。Voisard Asset Management Group Inc.在第三季度將其在藥明康德的持股增加了 9.7%。Voisard Asset Management Group Inc.現在持有 5,100 股公司股票，價值 134,000 美元，此前在上個季度又購買了 450 股。Central Pacific Bank Trust Division 在第四季度將其在藥明康德的持股增加了 33.3%。Central Pacific Bank Trust Division 現在持有 2,000 股公司股票，價值 51,000 美元，此前在此期間又購買了 500 股。Creative Planning 在第三季度將其在藥明康德的持股增加了 3.7%。Creative Planning 現在持有 18,477 股公司股票，價值 485,000 美元，此前在此期間又購買了 661 股。最後，亞利桑那州退休系統在第二季度將其在藥明康德的持股增加了 1.9%。亞利桑那州退休系統現在持有 37,939 股公司股票，價值 974,000 美元，此前在此期間又購買了 699 股。當前 95.91% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Perrigo Company Profile</h2>
<div class="lb-trans"><h2>藥明康德公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.</p>
<div class="lb-trans"><p>藥明康德公司提供非處方健康和保健解決方案，以提升個人在美國、歐洲和國際上的福祉。它通過消費者自我護理美洲和消費者自我護理國際兩個部門運營。該公司開發、製造、營銷和分銷自我護理消費品，如上呼吸道產品，包括止咳藥、祛痰藥以及鼻竇和過敏緩解藥；營養產品，包括嬰兒配方奶粉和營養飲料；消化健康產品，包括抗酸藥、止瀉藥和抗胃灼熱藥；止痛和助眠產品，包括止痛藥和退燒藥；以及口腔護理產品，包括牙刷、牙刷替換頭、牙線、牙線棒、美白產品和牙刷保護套。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Perrigo</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Driving Forward: Lucid’s Growing Sales and Gravity SUV's Impact</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Why Amazon’s Next Earnings Could Trigger a Stock Breakout</li>
<li>Best Stocks Under $10.00</li>
<li>With This Kind of Data, The Fed Isn’t Cutting Rates This Year</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票比藥明康德更好</li>
<li>哪些華爾街分析師最準確？</li>
<li>向前推進：Lucid 的銷售增長和 Gravity SUV 的影響</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>為什麼亞馬遜的下一個財報可能會引發股票突破</li>
<li>10 美元以下的最佳股票</li>
<li>有了這種數據，美聯儲今年不會降息</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Perrigo Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
</div><p>Before you consider Perrigo, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮藥明康德之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perrigo wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而培瑞克並不在名單上。</p>
</div><p>While Perrigo currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然培瑞克目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

培瑞克（紐約證券交易所代碼：PRGO）被 StockNews.com 降級為持有評級